Analytical Data
-
Gene name
CDK20
- Application
-
Alternative Names
CCRK; CDCH; p42; Cell Cycle Related Kinase; CDK-activating kinase p42; Cyclin-dependent protein kinase H; Cyclin-kinase-activating kinase p42
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9JHU3
-
Expression Region
Tyr4~Phe288
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK20, or Cyclin Dependent Kinase 20, is a member of the cyclin-dependent kinase (CDK) family, which plays a crucial role in regulating the cell cycle and various cellular processes through phosphorylation. The study of CDK20 has gained attention due to its potential implications in cancer biology, particularly in tumor progression and cell proliferation. Unlike other more characterized CDKs, the functional role of CDK20 remains less understood, prompting a need for in-depth research. Recent studies have suggested that CDK20 may influence cellular pathways that respond to DNA damage and contribute to the maintenance of genomic integrity. The overexpression or dysregulation of CDK20 has been observed in several cancer types, indicating its potential as a novel biomarker and therapeutic target. The generation and characterization of recombinant CDK20 protein are vital for elucidating its biochemical properties, interactions with cyclins, and its specific role in cell cycle regulation. By employing techniques such as molecular cloning and protein expression systems, researchers aim to produce sufficient quantities of CDK20 for functional assays. Understanding the molecular mechanisms by which CDK20 operates could provide new insights into its contributions to oncogenic processes and establish its utility in clinical applications for cancer diagnosis and treatment.
